[1]刘虹伶,王美佳,晏青霞.多发性骨髓瘤患者血清β2-微球蛋白、肿瘤坏死因子-α、乳酸脱氢酶检测及临床意义[J].陕西医学杂志,2024,(3):399-402.[doi:DOI:10.3969/j.issn.1000-7377.2024.03.024]
　LIU Hongling,WANG Meijia,YAN Qingxia.Detection and clinical significance of serum β2-microglobulin,tumor necrosis factor-α and lactate dehydrogenase in patients with multiple myeloma[J].,2024,(3):399-402.[doi:DOI:10.3969/j.issn.1000-7377.2024.03.024]
点击复制

多发性骨髓瘤患者血清β2-微球蛋白、肿瘤坏死因子-α、乳酸脱氢酶检测及临床意义
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2024年3期
页码:
399-402
栏目:
临床检验
出版日期:
2024-03-05

文章信息/Info

Title:
Detection and clinical significance of serum β2-microglobulin,tumor necrosis factor-α and lactate dehydrogenase in patients with multiple myeloma
作者:
刘虹伶; 王美佳; 晏青霞
(四川大学华西医院上锦医院 成都上锦南府医院血液内科,四川 成都 611730)
Author(s):
LIU Hongling; WANG Meijia; YAN Qingxia
(Department of Haematology,Shangjin Hospital,West China Hospital of Sichuan University,Chengdu 611730,China)
关键词:
多发性骨髓瘤;  β2-微球蛋白;  肿瘤坏死因子-α;  乳酸脱氢酶;  疗效;  疾病进展;  相关性
Keywords:
Multiple myeloma;  Beta 2-microglobulin;  Tumor necrosis factor-α;  Lactate dehydrogenase;  Efficacy;  Disease progression;  Correlation
分类号:
R 733.3
DOI:
DOI:10.3969/j.issn.1000-7377.2024.03.024
文献标志码:
A
摘要:
目的:检测多发性骨髓瘤患者血清β2-微球蛋白(β2-MG)、肿瘤坏死因子-α(TNF-α)、乳酸脱氢酶(LDH)水平,分析其临床意义。方法:选取多发性骨髓瘤患者101例为研究组,选取同期性别比例、年龄相似的非多发性骨髓瘤患者50例为对照组。比较两组血清β2-MG、TNF-α、LDH水平。比较不同Durie-Salmon分期及治疗前后多发性骨髓瘤患者血清β2-MG、TNF-α、LDH水平。比较治疗后不同疗效多发性骨髓瘤患者血清β2-MG、TNF-α、LDH水平并进行相关性分析。结果:研究组血清β2-MG、TNF-α、LDH水平明显高于对照组(均P<0.05)。Durie-Salmon分期Ⅲ期多发性骨髓瘤患者血清β2-MG、TNF-α、LDH水平高于Ⅰ期和Ⅱ期,Ⅱ期患者这些指标又高于Ⅰ期(均P<0.05)。治疗后,多发性骨髓瘤患者血清β2-MG、TNF-α、LDH水平较治疗前明显下降(均P<0.05)。不同疗效患者血清β2-MG、TNF-α、LDH水平比较差异有统计学意义(均P<0.05)。多发性骨髓瘤患者血清β2-MG、TNF-α、LDH水平与疗效正相关(r=0.862、0.396、0.885,均P<0.05)。结论:血清β2-MG、TNF-α、LDH参与多发性骨髓瘤疾病发生与发展过程,对三者进行检测有助于评估疾病进展及疗效。
Abstract:
Objective:To detect the levels of serum β2-microglobulin(β2-MG),tumor necrosis factor-α(TNF-α)and lactate dehydrogenase(LDH)in multiple myeloma patients,and to analyze clinical significance.Methods:A total of 101 patients with multiple myeloma were selected as the study group,and 50 non-multiple myeloma patients with similar gender ratio and age were selected as the control group.The serum levels of β2-MG,TNF-α and LDH were compared between the two groups.The serum levels of β2-MG,TNF-α and LDH in multiple myeloma patients with different Durie-Salmon stages and before and after treatmenwere compared.The levels of serum β2-MG,TNF-α and LDH in multiple myeloma patients with different therapeutic effects after treatment were compared and the correlation was analyzed.Results:The serum levels of β2-MG,TNF-α,and LDH in the study group were significantly higher than those in the control group(all P<0.05).The levels of serum β2-MG,TNF-α and LDH in patients with Durie-Salmon stage Ⅲ multiple myeloma were higher than those in stage Ⅰ and Ⅱ,and those in stage Ⅱ were higher than those in stage Ⅰ(all P<0.05).After treatment,the levels of serum β2-MG,TNF-α and LDH in patients with multiple myeloma were significantly lower than those before treatment(all P<0.05).There were statistically significant differences in serum β2-MG,TNF-α and LDH levels in multiple myeloma patients with different efficacy(all P<0.05).The levels of serum β2-MG,TNF-α and LDH in patients with multiple myeloma were positively correlated with the efficacy(r=0.862,0.396,0.885,all P<0.05).Conclusion:Serum β2-MG,TNF-α and LDH are involved in the occurrence and development of multiple myeloma,and the detection of the three levels is helpful to evaluate the disease progression and therapeutic effect.

参考文献/References:

[1] 杜娟英,薛海鲸.多发性骨髓瘤患者血清微小RNA-424、可溶性晚期糖基化终末产物受体、c-kit受体蛋白检测及临床意义[J].陕西医学杂志,2022,51(12):1585-1588,1592.
[2] 李迎巧,高二超,王茂生.杨淑莲治疗多发性骨髓瘤经验[J].陕西中医,2022,43(5):628-631,652.
[3] LIU J,LIU W,MI L,et al.Incidence and mortality of multiple myeloma in China,2006-2016:An analysis of the global burden of disease study 2016[J].J Hematol Oncol,2019,12(1):136.
[4] COWAN A J,GREEN D J,KWOK M,et al.Diagnosis and management of multiple myeloma:A review[J].JAMA,2022,327(5):464-477.
[5] 费晓莉,陶黎,熊梅,等.IL-37、VEGF、LDH和β2-MG在多发性骨髓瘤中的表达及其临床意义[J].重庆医学,2021,50(2):275-279.
[6] 韩少玲,吴亚兵,张家友,等.血清LDH和β2-MG水平与多发性骨髓瘤患者预后的相关性[J].实用癌症杂志,2020,35(11):1817-1820,1825.
[7] 黄天骄,周虹,刘松涛,等.弥漫大B细胞淋巴瘤患者血清中乳酸脱氢酶、β2微球蛋白及尿酸临床意义[J].临床血液学杂志,2021,34(6):412-414.
[8] 李炳宗,庄文卓,傅晋翔.TNF-α抑制多发性骨髓瘤患者骨髓间充质干细胞成骨潜能[J].江苏医药,2008,34(1):42-44.
[9] HUANG B,LU J,WANG X,et al.Prognostic value of lactate dehydrogenase in Chinese patients with newly diagnosed transplant eligible multiple myeloma[J].Leuk Lymphoma,2017,58(7):1740-1742.
[10] 中国医师协会血液科医师分会,中华医学会血液学分会,中国医师协会多发性骨髓瘤专业委员会.中国多发性骨髓瘤诊治指南(2017年修订)[J].中华内科杂志,2017,56(11):866-870.
[11] KUMAR S,PAIVA B,ANDERSON K C,et al.International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma[J].Lancet Oncol,2016,17(8):e328-e346.
[12] 王丽,赵艳莉,金瑄,等.多发性骨髓瘤患者的血清β2-MG、TNF-α、IL-6水平及其临床意义[J].海南医学,2020,31(12):1527-1529.
[13] 韩少玲,吴亚兵,张家友,等.多发性骨髓瘤患者血清β2-MG、CRP和IL-6水平与临床分期的关系[J].河北医药,2021,43(3):353-356.
[14] 贾蕾,何璇.多发性骨髓瘤合并肾功能损害患者预后的影响因素分析[J].解放军预防医学杂志,2021,39(1):87-89,105.
[15] HUANG Y,HUANG J,ZHANG P,et al.Integrated analysis of hub gene expression in multiple myeloma[J].J BUON,2021,26(5):2040-2052.
[16] 杨婧,何家锐,孙红兵,等.沙利度胺对类风湿关节炎滑膜细胞及外周血单个核细胞分泌肿瘤坏死因子-α和血管内皮生长因子的影响及机制研究[J].陕西医学杂志,2022,51(12):1501-1504,1510.
[17] ALYMATIRI C M,GKEGKA G T,GAVRIATOPOULOU M,et al.Association of -308G/A,-238G/A TNF-α polymorphisms with multiple myeloma risk and survival:A systematic review and meta-analysis[J].Clin Lymphoma Myeloma Leuk,2022,22(2):e96-e115.
[18] 马振旺,梁浩,赵兵,等.透穴刺法对帕金森病焦虑大鼠杏仁核TNF-α和IL-10表达的影响[J].陕西中医,2021,42(9):1171-1174.
[19] 马玉,李研,骆亚莉,等.肿瘤坏死因子-α在慢性炎症与肿瘤发生中的作用[J].中国临床药理学杂志,2022,38(12):1419-1423.
[20] 辉红蕾,周晋宇,段秋婷,等.多发性骨髓瘤的信号通路及其靶向治疗的研究进展[J].现代肿瘤医学,2022,30(10):1902-1906.
[21] ROY M,SINGH K,SHINDE A,et al.TNF-α-induced E3 ligase,TRIM15 inhibits TNF-α-regulated NF-κB pathway by promoting turnover of K63 linked ubiquitination of TAK1[J].Cell Signal,2022,91:110210.
[22] AGARWAL P,LI H,CHOI K,et al.TNF-α-induced alterations in stromal progenitors enhance leukemic stem cell growth via CXCR2 signaling[J].Cell Rep,2021,36(2):109386.
[23] MIHOLJCIC T B S,HALSE H,BONVALET M,et al.Rationale for LDH-targeted cancer immunotherapy[J].Eur J Cancer,2023,181:166-178.
[24] DING J,KARP J E,EMADI A.Elevated lactate dehydrogenase(LDH)can be a marker of immune suppression in cancer:Interplay between hematologic and solid neoplastic clones and their microenvironments[J].Cancer Biomark,2017,19(4):353-363.
[25] 陈浩宇,陆秀盼,陈丽娟,等.血清乳酸脱氢酶水平与初诊老年多发性骨髓瘤病人预后的相关性分析[J].实用老年医学,2021,35(1):36-40.
[26] 邱惠,沈爱东,孙志军,等.8例多发性骨髓瘤致心肌淀粉样变性临床特点分析[J].中国心血管杂志,2018,23(3):219-223.
[27] HE H,LIU J,JIANG H,et al.High serum lactate dehydrogenase adds prognostic value to cardiac biomarker staging system for light chain amyloidosis[J].J Cancer,2019,10(23):5622-5627.

相似文献/References:

[1]朱清红,李德奎,罗 英.血清尿酸、β2微球蛋白和尿液轻链联合检测〖JZ〗在多发性骨髓瘤早期诊断中的应用[J].陕西医学杂志,2019,(9):1235.
　ZHU Qinghong,LI Dekui,LUO Ying..Combined detection of serum uric acid，β2 microglobulin and urine light chain〖JZ〗in early diagnosis of multiple myeloma[J].,2019,(3):1235.
[2]靳娟娟,姚 玉.MutT同系物1抑制剂对多发性骨髓瘤细胞增殖和凋亡的影响[J].陕西医学杂志,2021,50(8):934.[doi:DOI:10.3969/j.issn.1000-7377.2021.08.008]
　JIN Juanjuan,YAO Yu.Effect of MutT homologue-1 inhibitor on proliferation and apoptosis of multiple myeloma cells[J].,2021,50(3):934.[doi:DOI:10.3969/j.issn.1000-7377.2021.08.008]
[3]杜娟英,薛海鲸.多发性骨髓瘤患者血清微小RNA-424、可溶性晚期糖基化终末产物受体、c-kit受体蛋白检测及临床意义[J].陕西医学杂志,2022,51(12):1585.[doi:DOI:10.3969/j.issn.1000-7377.2022.12.028]
　DU Juanying,XUE Haijing.Detection and clinical significance of serum miR-424,sRAGE and CD117 in patients with multiple myeloma[J].,2022,51(3):1585.[doi:DOI:10.3969/j.issn.1000-7377.2022.12.028]
[4]张治业,余醒醒,张 璐,等.CD166对多发性骨髓瘤RPMI-8226细胞增殖、凋亡及自噬的影响实验研究[J].陕西医学杂志,2023,52(12):1675.[doi:DOI:10.3969/j.issn.1000-7377.2023.12.010]
　ZHANG Zhiye,YU Xingxing,ZHANG Lu,et al.Effects of CD166 on proliferation,apoptosis and autophagy of multiple myeloma RPMI-8226 cells[J].,2023,52(3):1675.[doi:DOI:10.3969/j.issn.1000-7377.2023.12.010]
[5]滕 远,李莉娟,张连生.髓细胞白血病1抑制剂在多发性骨髓瘤治疗中的研究进展[J].陕西医学杂志,2024,(6):858.[doi:DOI:10.3969/j.issn.1000-7377.2024.06.029]
　TENG Yuan,LI Lijuan,ZHANG Liansheng.Research progress of myeloid cell leukemia 1 inhibitors in treatment of multiple myeloma[J].,2024,(3):858.[doi:DOI:10.3969/j.issn.1000-7377.2024.06.029]
[6]凌 峰,薛 珺,章 钟,等.微创经皮肾镜碎石取石术小剂量地塞米松干预对肾结石疗效影响价值研究[J].陕西医学杂志,2024,(8):1077.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.015]
　LING Feng,XUE Jun,ZHANG Zhong,et al.Effect of low-dose dexamethasone intervention in minimally invasive percutaneous nephrolithotomy on the efficacy of kidney stones[J].,2024,(3):1077.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.015]
[7]冷朝会,李雪莲,刘 俊,等.热休克蛋白90α、β2-微球蛋白及胃泌素释放肽前体在肺癌患者血清中的表达水平及检测意义[J].陕西医学杂志,2024,(8):1110.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.023]
　LENG Chaohui,LI Xuelian,LIU Jun,et al.Expression levels and significance of heat shock protein 90α,β2-microglobulin and pro-gastrin releasing peptide in the serum of patients with lung cancer[J].,2024,(3):1110.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.023]
[8]赵思捷,余 航,党珮珠,等.多发性骨髓瘤患者合并心包积液危险因素分析及列线图预测模型构建[J].陕西医学杂志,2024,(12):1635.[doi:DOI:10.3969/j.issn.1000-7377.2024.12.009]
　ZHAO Sijie,YU Hang,DANG Peizhu,et al.Risk factors of multiple myeloma patients with pericardial effusion and construction of nomogram prediction model[J].,2024,(3):1635.[doi:DOI:10.3969/j.issn.1000-7377.2024.12.009]

备注/Memo

备注/Memo:
基金项目:四川省科技计划项目(2020YFS0255)
更新日期/Last Update: 2024-03-05